WO2017177908A1 - Protéines recombinantes pd-l1 et pd-l2 et leurs utilisations - Google Patents

Protéines recombinantes pd-l1 et pd-l2 et leurs utilisations Download PDF

Info

Publication number
WO2017177908A1
WO2017177908A1 PCT/CN2017/080144 CN2017080144W WO2017177908A1 WO 2017177908 A1 WO2017177908 A1 WO 2017177908A1 CN 2017080144 W CN2017080144 W CN 2017080144W WO 2017177908 A1 WO2017177908 A1 WO 2017177908A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
recombinant protein
patient
cells
construct
Prior art date
Application number
PCT/CN2017/080144
Other languages
English (en)
Chinese (zh)
Inventor
陈思毅
Original Assignee
北京普纳生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京普纳生物科技有限公司 filed Critical 北京普纳生物科技有限公司
Publication of WO2017177908A1 publication Critical patent/WO2017177908A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to the field of bioengineering, and in particular, to recombinant proteins and uses thereof.
  • Targeted therapies mainly include monoclonal antibodies (sometimes classified as passive cell transfusion and tumor vaccines, immunotherapy through the immune system of the motivational body, enhanced tumor microenvironment anti-tumor immunotherapy) and small molecule targeted drugs, while immunotherapy It mainly includes cytokine therapy, immunoassay monoclonal antibody, and adoptive immunotherapy to control and kill tumor cells. Therefore, it has the advantages of high efficiency, high specificity and good tolerance, and has broad prospects in cancer therapy.
  • Tumor immunotherapy vaccines mainly include tumor cell vaccines, dendritic cell (DC cell) vaccines, protein & peptide vaccines, nucleic acid vaccines, genetically engineered vaccines and anti-idiotype tumor vaccines.
  • the main mechanism by which these vaccines can kill tumors is through The patient is directed against a tumor-specific antigen immune response, including antibody response and cytotoxic T lymphocyte (CTL) specific killing.
  • CTL cytotoxic T lymphocyte
  • tumor vaccines target tumor-associated antigens, and their clinical efficacy is weak, and further research and development are needed to enhance clinical efficacy.
  • Tumor cells highly express immune checkpoint molecules PD-L1 or PD-L2, and activated cytotoxic T lymphocytes on the surface
  • PD-1 which inhibits the T lymphocyte response of the tumor, escapes the immune killing of cytotoxic T lymphocytes.
  • CTL immune cells-cytotoxic T lymphocytes
  • an object of the present invention is to provide a recombinant PD-L1 protein having an immune response which causes a tumor-specific antigen, which is actively stimulated to produce an anti-PD-L1 antibody in a patient, and the patient has been mobilized.
  • the presence of spontaneously induced immune cell CTLs is induced and stimulates the production of new anti-PD-L1 CTLs, which in turn specifically kill tumor cells.
  • the active immune killing effect on tumor cells caused by the recombinant protein proposed by the invention is remarkable.
  • the invention proposes a recombinant protein.
  • the recombinant protein comprises: an immunological checkpoint molecule fragment; a helper T cell epitope fragment; and an immunostimulatory molecule fragment.
  • the recombinant protein proposed in the embodiments of the present invention can continuously stimulate the production of anti-immunization checkpoint antibodies in vivo, mobilize the spontaneously induced immune cell CTLs existing in the body, and stimulate the production of CTLs against the immune checkpoints, thereby specifically killing the tumor cells. .
  • the active immune killing effect on tumor cells caused by the recombinant protein proposed by the embodiments of the present invention is remarkable.
  • the recombinant protein may further comprise at least one of the following additional technical features:
  • the immune checkpoint molecule is PD-L1 or PD-L2.
  • PD-L1 or PD-L2 is specifically expressed in tumor cells, and the specificity of the tumor antigen immune response caused by the recombinant protein proposed in the examples of the present invention is stronger.
  • the immunological checkpoint molecule fragment is an extracellular molecular fragment of the PD-L1 or PD-L2 removal transmembrane region.
  • the extracellular molecular fragment of PD-L1 or PD-L2 in the transmembrane region has only tumor antigenicity and does not have tumor immunosuppressive function, and thus the extracellular molecular fragment of PD-L1 or PD-L2 in the transmembrane region can be further removed.
  • the specificity is further improved.
  • the helper T cell epitope is a broad spectrum PADRE helper T cell epitope.
  • Broad-spectrum PADRE-assisted T cell epitopes can effectively activate helper T cells, thereby further enhancing the specific killing of cytotoxic T lymphocytes (CTLs) caused by recombinant proteins.
  • CTLs cytotoxic T lymphocytes
  • the immunostimulatory molecule is a granulocyte colony-stimulating biological factor, interleukin-12 or a chemokine.
  • the above immunostimulatory molecule has biological activity, can significantly enhance the antigen presenting function of dendritic cells (DC cells) and enhance the activity of cytotoxic T lymphocytes (CTLs) and B lymphocytes, and the recombinant protein of the embodiments of the present invention can be further To effectively cause tumor antigen immune response.
  • the N-terminus of the helper T cell epitope fragment is linked to the C-terminus of the immunological checkpoint molecule fragment, and the C-terminus of the helper T cell epitope fragment and the immunostimulatory molecule fragment N ends are connected.
  • the related molecular fragment in the recombinant protein of the present invention facilitates the presentation of the tumor antigen PD-L1 or PD-L2 fragment in DC cells, and is beneficial to the help of T cell epitopes and immunostimulatory molecules.
  • the corresponding function of activating immune cells, and thus the recombinant protein of the examples of the present invention can more effectively cause a tumor antigen immune response.
  • the invention proposes a recombinant protein.
  • the recombinant protein has the amino acid sequences shown in SEQ ID NOS: 1 to 9.
  • the recombinant protein proposed in the embodiment of the present invention can cause a tumor-specific antigen immune response, and the protein stimulates the production of anti-PD-L1 or PD-L2 antibody in the patient by active immunization, and mobilizes the spontaneous induction of the existing in the patient.
  • the cells are immunized with CTL and stimulated to produce anti-PD-L1 or PD-L2 CTL, thereby specifically killing tumor cells.
  • the active immune killing effect on tumor cells caused by the recombinant protein proposed by the invention is remarkable.
  • the invention proposes a nucleic acid.
  • the nucleic acid encodes the recombinant protein described above, and the nucleic acid has the nucleotide sequence shown in SEQ ID NOS: 10 to 18.
  • the recombinant protein encoded by the nucleic acid according to the embodiment of the present invention stimulates the production of anti-PD-L1 or PD-L2 antibody in the patient by active immunization, mobilizes the spontaneously induced immune cell CTL which has already existed in the patient, and stimulates the production of anti-drug.
  • PD-L1 or PD-L2CTL which specifically kills tumor cells.
  • the active immune killing effect on tumor cells caused by the recombinant protein proposed by the invention is remarkable.
  • the invention proposes a construct.
  • the construct Carry the nucleic acid described above.
  • the construct introduced into the recipient cell of the present invention can achieve high-efficiency expression of the nucleic acid described above, and thereby efficiently express the recombinant protein described above in the recipient cell.
  • the construct may further comprise at least one of the following additional technical features:
  • the vector of the construct is a pET series vector, a pPIC series vector, a BacPAK, a pSV series vector or a pCMV series vector.
  • the above vector of the embodiment of the present invention can achieve further efficient expression of the above recombinant protein in prokaryotic cells or eukaryotic cells.
  • the invention proposes a construct.
  • the construct carries the following nucleic acid molecule: (1) a nucleic acid molecule encoding a fragment of an immunological checkpoint molecule having the amino acid sequence set forth in SEQ ID NOS: 19-21,
  • the nucleic acid molecule encoding the immunological checkpoint molecule fragment has the nucleotide sequence shown in SEQ ID NOS: 22-24; (2) the nucleic acid molecule encoding the helper T cell epitope fragment, the helper T cell epitope
  • the fragment has the amino acid sequence set forth in SEQ ID NO: 25, the nucleic acid molecule encoding the helper T cell epitope fragment has the nucleotide sequence set forth in SEQ ID NO: 26; and (3) the fragment encoding the immunostimulatory molecule
  • the nucleic acid molecule having the amino acid sequence of SEQ ID NOS: 27 to 29, and the nucleic acid molecule encoding the immunostimulatory molecule fragment has the following nucleic acid molecule: (1)
  • the construct according to the embodiment of the present invention efficiently expresses a recombinant protein containing an immunological checkpoint molecular fragment, a helper T cell epitope fragment and an immunostimulatory molecule fragment in a recipient cell, and the recombinant protein is actively immunized.
  • the patient stimulates the production of anti-PD-L1 antibody, mobilizes the spontaneously induced immune cell CTL already present in the patient, and stimulates the production of anti-PD-L1CTL, thereby specifically killing the tumor cells.
  • the invention provides a transgenic cell.
  • the transgenic cell carries a construct as described above.
  • the transgenic cells proposed in the embodiments of the present invention can express the recombinant protein as described above, and the obtained recombinant protein stimulates an anti-immunological checkpoint, such as PD-L1 or PD-L2 antibody, by active immunization, and mobilizes.
  • an anti-immunological checkpoint such as PD-L1 or PD-L2 antibody
  • Spontaneously induced immune cell CTLs already present in the patient and stimulate the production of anti-immunological checkpoints, such as PD-L1 or PD-L2 CTL, which specifically kill tumor cells.
  • the transgenic cell may further comprise at least one of the following additional technical features:
  • the transgenic cells are BL21, BL21 (DE3), BL21 (DE3) pLysS, DH10B, XL1-Blue, Pichia pastors, Kluyveromyces lactis, Sf9, Sf21, High-Five T, CHO cell line, HEK cell line, Hela cell line or COS cell line.
  • the transgenic cell can efficiently express the recombinant protein described above, and then the recombinant protein obtained by protein purification can be administered to a patient, and the patient can be further effectively stimulated to produce anti-PD in the patient by active immunization.
  • the -L1 or PD-L2 antibody mobilizes spontaneously induced immune cell CTLs already present in the patient and stimulates the production of anti-PD-L1 or PD-L2CTL, thereby specifically killing the tumor cells.
  • the transgenic cell is an antigen presenting cell.
  • the antigen presenting cell is derived from a patient, and the antigen presenting cell carrying the aforementioned construct can be further input into the patient, thereby realizing the continuous expression of the recombinant protein described above in the patient, and further Actively immunizing in the body to produce anti-PD-L1 or PD-L2 antibodies in vivo, mobilizing the spontaneously induced immune cell CTLs already present in the patient, and stimulating the production of anti-PD-L1 or PD-L2CTL, Specific killing of tumor cells.
  • the transgenic cell is a DC cell.
  • the DC cells have an antigen-presenting function, and the DC cells derived from the patient themselves carry the aforementioned construct and are returned to the patient, thereby realizing the high-efficiency expression of the recombinant protein described above in the patient and the tumor antigen PD-L1.
  • PD-L2 is efficiently presented on the surface of DC cells, thereby further effectively stimulating the production of anti-PD-L1 or PD-L2 antibodies, mobilizing the spontaneously induced immune cell CTLs already present in the patient, and stimulating the production of anti-PD-L1 or PD -L2CTL, which further effectively kills tumor cells specifically.
  • the invention provides the use of a recombinant protein as described above for the preparation of a medicament for the prevention or treatment of a tumor.
  • the recombinant protein proposed by the embodiments of the present invention can cause a significant tumor-specific antigen immune response in a tumor patient, and effectively stimulates the production of an anti-immunological checkpoint, such as PD-L1 or PD-L2 antibody, to mobilize the spontaneous induction already existing in the patient.
  • the resulting immune cell CTL is stimulated to produce an anti-immunological checkpoint, such as PD-L1 or PD-L2CTL, which effectively kills the tumor cells specifically.
  • the inventors further verified through experiments that The recombinant protein proposed in the examples of the present invention has utility in the preparation of a medicament effective for preventing or treating a tumor.
  • the invention provides the use of a recombinant protein as described above for the preparation of a vaccine for the prevention or treatment of a tumor.
  • the recombinant protein proposed by the embodiments of the present invention can cause a significant tumor-specific antigen immune response in a tumor patient, and effectively stimulates the production of an anti-immunological checkpoint, such as PD-L1 or PD-L2 antibody, to mobilize the spontaneous induction already existing in the patient.
  • the resulting immune cell CTL is stimulated to produce an anti-immunological checkpoint, such as PD-L1 or PD-L2CTL, which effectively kills the tumor cells specifically.
  • the recombinant protein proposed in the examples of the present invention has a use in preparing a vaccine effective for preventing or treating a tumor.
  • the invention provides the use of a recombinant protein as described above for the preparation of a vaccine for the treatment of a viral infection.
  • the inventors have found that HBV, HCV, HIV, EBV virus-infected cells express PD-L1, and the vaccine prepared by the recombinant protein of the present invention can stimulate anti-PD-L1 in a patient.
  • the antibody mobilizes spontaneously induced immune cell CTLs already present in the patient and stimulates the production of anti-immunological checkpoints, such as PD-L1 CTL, to effectively kill cells infected with the above virus.
  • the invention provides a pharmaceutical composition.
  • the pharmaceutical composition comprises: the recombinant protein described above; and a pharmaceutically acceptable adjuvant.
  • the recombinant protein in the pharmaceutical composition proposed in the examples of the present invention can cause a significant specific antigen immune response, and the function of the adjuvant to enhance the immune response.
  • the pharmaceutical composition provided by the embodiment of the present invention effectively stimulates an anti-immunization checkpoint, such as a PD-L1 or PD-L2 antibody, to mobilize an already existing spontaneously induced immune cell in a patient. CTL, and stimulate the production of anti-immunological checkpoints, such as PD-L1 or PD-L2CTL, to effectively kill tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
  • viruses HBV, HCV, HIV, EBV
  • the invention proposes a DC cell.
  • the DC cells are loaded with the recombinant protein described above.
  • the DC cells proposed in the embodiments of the present invention can present antigens in the recombinant protein (such as the immunological checkpoint molecular fragment described above), helper T cell epitope fragments, and immunostimulatory molecule fragments, respectively.
  • anti-immunological checkpoints such as PD-L1 or PD-L2 antibodies
  • mobilizes spontaneously induced immune cell CTLs already present in patients and stimulates the production of anti-immune checkpoints such as PD-L1 or PD-L2CTL, in turn, effectively kills tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
  • viruses HBV, HCV, HIV, EBV
  • the invention provides a targeted immune cell population.
  • the targeted immune cell population is obtained by co-culture of DC cells with lymphocytes as described above.
  • the targeted immune cell population proposed in the embodiments of the present invention can specifically kill tumor cells, secrete antibodies that specifically bind tumor antigens, and achieve specific removal of tumor cells.
  • the invention proposes a vaccine.
  • the vaccine comprises a recombinant protein as described above, a DC cell as described above or a targeted immune cell population as described above.
  • the recombinant protein, DC cell and targeted immune cell population proposed by the embodiments of the present invention can cause a significant specific antigen immune response in a patient.
  • the vaccine according to the embodiment of the present invention can effectively stimulate the production of an anti-immunization checkpoint, such as a PD-L1 or PD-L2 antibody, mobilize the spontaneously induced immune cell CTL already existing in the patient, and stimulate An anti-immunization checkpoint, such as PD-L1 or PD-L2CTL, is generated to effectively kill tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
  • an anti-immunization checkpoint such as a PD-L1 or PD-L2 antibody
  • the invention provides an antibody.
  • the antibody specifically recognizes the recombinant protein described above, and the antibody proposed in the embodiment of the present invention specifically recognizes a tumor antigen.
  • the invention finds that the antibody specifically recognizes an antigen and specifically binds to a tumor cell or a cell infected by a virus (H BV, HCV, HIV, EBV), thereby causing the tumor cell or the virus to be infected ( Cells infected with HBV, HCV, HIV, EBV) are engulfed by phagocytic cells to achieve specific clearance of tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
  • the invention provides a method of preparing an antibody.
  • the method comprises: immunizing an animal with the recombinant protein described above; collecting serum of the immunized animal; and purifying the antibody of interest from the serum.
  • the method for preparing an antibody proposed in the embodiments of the present invention is simple and convenient, and the antibody can specifically recognize the recombinant protein.
  • the invention provides a therapeutic composition.
  • the therapeutic composition comprises: a recombinant protein as described above, a nucleic acid as described above, a construct as described above, a transgenic cell as described above, a pharmaceutical composition as described above, a front The DC cells, the aforementioned targeted immune cell population, the vaccine described above or the antibodies described above.
  • the therapeutic composition proposed by the embodiments of the present invention can directly or indirectly cause a specific antigen immune response, and achieve specificity to tumor cells or cells infected by viruses (HBV, HCV, HIV, EBV). Kill and clear.
  • the invention provides a method of stimulating anti-PD-L1 antibody production or cytotoxic T lymphocyte response in a patient.
  • the method is achieved by at least one of the following: 1) the recombinant protein described above is co-cultured with DC cells taken from a patient, and the DC of the recombinant protein described above is loaded The cells are returned to the patient; 2) the patient is administered the pharmaceutical composition described above; 3) the previously described construct is introduced into the DC cells taken from the patient, and the DC cells introduced into the construct are returned to the patient. In vivo; and 4) administering to the patient a construct as described above.
  • the manner proposed in the examples of the present invention can significantly stimulate anti-PD-L1 antibody production or cytotoxic T lymphocyte reaction in a patient.
  • the invention provides a method of treating cancer. According to an embodiment of the present invention, it is achieved by at least one of the following methods: 1) the recombinant protein described above is co-cultured with DC cells taken from a cancer patient, and the DC cells loaded with the recombinant protein described above are returned. Loss to a cancer patient; 2) administration of the aforementioned pharmaceutical composition to a cancer patient; 3) introduction of the aforementioned construct into DC cells taken from a cancer patient, and introduction into the body The DC cells of the construct are returned to the cancer patient; and 4) the cancer patient is administered the construct described above.
  • the method proposed by the embodiments of the present invention can directly or indirectly cause a specific antigen immune response, and achieve specific killing and elimination of tumor cells.
  • the invention provides a method of treating a patient infected with a virus.
  • it is achieved by at least one of the following methods: 1) the recombinant protein described above is co-cultured with DC cells taken from a patient, and the DC cells loaded with the recombinant protein described above are returned.
  • the patient is administered the construct described above.
  • the method proposed by the embodiments of the present invention can directly or indirectly cause a specific antigen immune reaction, and achieve specific killing and elimination of cells infected by viruses (HBV, HCV, HIV, EBV), thereby effectively treating patients infected with the virus.
  • the above method may further include at least one of the following additional technical features:
  • the virus comprises at least one selected from the group consisting of HBV, HCV, HIV and EBV. Further effective treatment of patients infected with HBV, HCV, HIV or EBV can be achieved using the above method according to an embodiment of the invention.
  • FIG. 1 is a schematic view showing the structure of a fusion protein according to an embodiment of the present invention.
  • PD-L1 ⁇ -PADRE Th-GM-CSF fusion protein
  • PD-L1 ⁇ -PADRE Th-GM-CSF fusion protein
  • PD-L1 ⁇ -PADRE Th-GM-CSF a fusion protein capable of significantly controlling the growth of PD-L1 + lung cancer according to an embodiment of the present invention.
  • first and second are used for descriptive purposes only, and are not to be construed as indicating or implying a relative importance or implicitly indicating the number of technical features indicated. Thus, features defining “first” and “second” may include one or more of the features either explicitly or implicitly. Further, in the description of the present invention, the meaning of "a plurality" is two or more unless otherwise specified.
  • the invention proposes a recombinant protein.
  • the recombinant protein comprises: an immunological checkpoint molecule fragment; a helper T cell epitope fragment; and an immunostimulatory molecule fragment.
  • the recombinant protein proposed in the embodiments of the present invention stimulates the production of anti-immunological checkpoint antibodies in the patient, mobilizes the spontaneously induced immune cell CTLs already existing in the body, and stimulates the production of CTLs against the immune checkpoints, thereby specifically killing the tumor cells.
  • the active immune killing effect on tumor cells caused by the recombinant protein proposed by the embodiments of the present invention is remarkable.
  • the immune checkpoint molecule may be selected from, but not limited to, at least one of PD-L1 and PD-L2.
  • PD-L1 or PD-L2 is specifically expressed in tumor cells, and the specificity of the tumor antigen immune response caused by the recombinant protein proposed in the examples of the present invention is stronger.
  • the immunological checkpoint molecule fragment is an extracellular molecular fragment (PD-L1 ⁇ /PD-L2 ⁇ ) of the transmembrane region of the PD-L1 or PD-L2.
  • the extracellular molecular fragment of the PD-L1 or PD-L2 removal transmembrane region has only tumor antigenicity and does not have tumor immunosuppressive function, and then the extracellular molecular fragment of the transmembrane region of PD-L1 or PD-L2 is antigen-removed.
  • Presenting cells such as DC cells are presented on the surface of the cells, which can effectively elicit a tumor antigen immune response, and the specificity is further improved.
  • the helper T cell epitope can be a broad spectrum PADRE helper T cell epitope (PADRE Th).
  • PADRE Th PADRE helper T cell epitope
  • the broad-spectrum PADRE helper T cell epitope is an epitope peptide that binds to a broad spectrum of human leukocyte antigen DR (HLA-DR) with high affinity or intermediate affinity and 16 of the most prevalent HLA- 15 of the DR types are combined. Because of its universal binding, PADRE needs to overcome the problems caused by the diversity of HLA-DR molecules in the population. PADRE acts as a helper T cell epitope and binds to the antigen. After binding, it activates the Ag-specific antigen reaction efficiently and for a long time.
  • HLA-DR human leukocyte antigen DR
  • the PADRE peptide is specifically processed to immunologically activate helper T lymphocyte 1 (Th1) in humans to assist in the activation of killer immune T cells and to activate helper T lymphocyte 2 (Th2) to assist B lymphocytes to secrete antibodies, thereby Further enhancing the antigenic immune response caused by the recombinant protein.
  • Th1 helper T lymphocyte 1
  • Th2 helper T lymphocyte 2
  • the immunostimulatory molecule may be selected from the group consisting of granulocyte colony stimulating biological factor (GM-CSF), interleukin-12 (IL-12) or chemokine (RANTES).
  • GM-CSF granulocyte colony stimulating biological factor
  • IL-12 interleukin-12
  • RANTES chemokine
  • GM-CSF is used to enhance the immune response in animal models and clinical trials.
  • immunotherapy GM-CSF is also widely used as an adjuvant to enhance the immune response.
  • tumor cells are irradiated by radiation, which secretes GM-CSF to stimulate a potent, specific, and prolonged anti-tumor immune response. This immunization induces infiltration of CD4+ and CD8+ T lymphocytes and plasma cells in metastatic lesions of advanced melanoma, which in turn causes necrosis of a large number of tumor cells.
  • GM-CSF The immunopotentiating effect of secreting tumor cells and GM-CSF are capable of recruiting DC cells and maturation and activation of DC cells, thereby activating the role of immune killing of T lymphocytes and B lymphocytes.
  • the GM-CSF in the recombinant protein proposed by the embodiment of the present invention can significantly enhance the antigen presentation of dendritic cells (DC cells).
  • DC cells dendritic cells
  • CTL cytotoxic T lymphocytes
  • B lymphocytes are enhanced, and the recombinant protein of the embodiment of the present invention can more effectively induce a tumor antigen immune response.
  • Chemokines control the migration of specific leukocyte populations in immune responses, hematopoiesis, and routine immune surveillance.
  • RANTES regulated upon activation normal T-cell expressed, CCL5
  • CCL5 normal T-cell expressed, CCL5
  • CCL5 regulated upon activation normal T-cell expressed
  • IL-12 is a pleiotropic cytokine that activates the association between autoimmune and adaptive immunity. Based on its response, IL-12 is considered to be "cytotoxic lymphocyte maturation factor" and "natural killer cell stimulating factor". Since IL-12 can establish the correlation between autoimmune and adaptive immunity, it can strongly stimulate the production of IFN- ⁇ -a, thereby coordinating the body's own anti-cancer mechanism. IL-12 has been used in the human body for immunotherapy of tumors. IL-12 plays a role in a variety of immune cells, including T lymphocytes and B lymphocytes. IL-12 plays a key role in promoting the anti-tumor immune response of Th1 cells.
  • the ligation sequence of the helper T cell epitope fragment and the immunostimulatory molecule fragment is as follows: the N-terminus of the helper T cell epitope is linked to the C-terminus of the immunological checkpoint molecule fragment, and the helper T cell epitope fragment C-end and The N-terminus of the immunostimulatory molecule fragment is linked.
  • the corresponding molecular fragment in the recombinant protein of the present invention can be presented on the surface of the DC cell, respectively.
  • APCs main antigen-presenting cells
  • the recombinant protein proposed by the embodiments of the present invention allows DC cells to present intracellular antigens to the cell surface, which is presented to the MHC class II by endocytic pathway, and is presented to the MHC class I by a cross-priming pathway, thereby leading to the production of antigen-specific Th cells. Reacts with CTL cells.
  • the recombinant protein presented by the embodiments of the present invention causes a strong antibody response on the surface of DC cells. It has long been believed that the activation of humoral responses by DC cells is achieved by the interaction of T lymphocytes and B lymphocytes by CD4+ Th cells. However, existing in vitro and in vivo experiments have demonstrated that DC cells activate a humoral response as a direct mode of action.
  • DC cells have been shown to strongly promote cell differentiation and production of antibodies to CD40-activated B lymphocytes. Inoculation of antigen-loaded DC cells is capable of inducing a protective humoral immune response.
  • the recombinant protein of the embodiments of the present invention can more effectively cause a tumor antigen immune response.
  • the recombinant protein has the amino acid sequences shown in SEQ ID NOS: 1 to 9.
  • SEQ ID NO: 1 is the amino acid sequence of human PD-L1 ⁇ -PADRE Th-human GM-CSF recombinant protein
  • SEQ ID NO: 2 is the amino acid sequence of human PD-L1 ⁇ -PADRE Th-human RANTES recombinant protein
  • SEQ ID NO:3 is the amino acid sequence of human PD-L1 ⁇ -PADRE Th-IL-12 recombinant protein
  • SEQ ID NO: 4 is the amino acid sequence of human PD-L2 ⁇ -PADRE Th-human GM-CSF recombinant protein
  • SEQ ID NO: 5 is Human PD-L2 ⁇ -PADRE
  • SEQ ID NO: 6 is the amino acid sequence of the human PD-L2 ⁇ -PADRE Th-human IL-12 recombinant
  • the present invention proposes a nucleic acid encoding the recombinant protein described above, and according to an embodiment of the present invention, the nucleic acid encoding the recombinant protein described above has the nucleotide sequences shown in SEQ ID NOS: 10 to 18.
  • SEQ ID NO: 10 is the nucleotide sequence of a nucleic acid encoding a human PD-L1 ⁇ -PADRE Th-human GM-CSF recombinant protein
  • SEQ ID NO: 11 is a recombinant protein encoding human PD-L1 ⁇ -PADRE Th-human RANTES
  • the nucleotide sequence of the nucleic acid, SEQ ID NO: 12 is the nucleotide sequence of the nucleic acid encoding the human PD-L1 ⁇ -PADRE Th-IL-12 recombinant protein
  • SEQ ID NO: 13 is the encoding human PD-L2 ⁇ -PADRE Th-
  • SEQ ID NO: 14 is the nucleotide sequence of the nucleic acid encoding the human PD-L2 ⁇ -PADRE Th-human RANTES recombinant protein
  • SEQ ID NO: 11 is a recombinant protein encoding human PD-L1 ⁇ -PAD
  • the recombinant protein encoded by the nucleic acid proposed in the embodiments of the present invention can cause tumor-specific antigen immune response, cause specific killing of cytotoxic T lymphocytes (CTL) and secrete specific antibodies of B cells, and achieve specificity to tumor cells. Killing.
  • CTL cytotoxic T lymphocytes
  • the present invention proposes a construct which carries the nucleic acid described above.
  • the construct introduced into the recipient cell of the embodiment of the present invention can achieve high-efficiency expression of the nucleic acid described above, thereby efficiently expressing the recombinant protein described above in the recipient cell.
  • the vector of the construct is a pET series vector, a pGEX series vector, a pPIC series vector, a BacPAK, a pSV series vector or a pCMV series vector, wherein the pET series vector is in the T7 promoter in E.
  • coli Down-regulated expression of recombinant protein pGEX series vectors were used to regulate the expression of recombinant proteins in E. coli under the tac promoter, pPIC series vectors were used to regulate the expression of recombinant proteins in yeast under the AOX1 promoter, and BacPAK vectors were used in Recombinant proteins are expressed in baculovirus under the control of the pPolh promoter, and the pSV series vector or pCMV series vectors are used to express recombinant proteins in mammalian cells under the control of the CMV, SV40 and (EF)-1 promoters.
  • the above vector of the embodiment of the present invention can achieve further efficient expression of the above recombinant protein in prokaryotic cells or eukaryotic cells.
  • the above construct carries the following nucleic acid molecules: (1) encoding an immunological checkpoint molecule A nucleic acid molecule of the fragment having the amino acid sequence of SEQ ID NOS: 19 to 21, wherein SEQ ID NO: 19 is the amino acid sequence of human PD-L1 ⁇ , and SEQ ID NO: 20 is human PD-L2 ⁇
  • the amino acid sequence of SEQ ID NO: 21 is the amino acid sequence of human PD-L1-PD-L2 ⁇
  • the nucleic acid molecule encoding the immunological checkpoint molecule fragment has the nucleotide sequence shown by SEQ ID NOs: 22-24, wherein SEQ ID NO: 22 is the nucleotide sequence of a nucleic acid molecule encoding human PD-L1 ⁇ , SEQ ID NO: 23 is the nucleotide sequence of a nucleic acid molecule encoding human PD-L2 ⁇ , and SEQ ID NO: 24 is encoding a human PD- a
  • the vector of the construct is a prokaryotic or eukaryotic protein expression vector.
  • the construct according to the embodiment of the present invention efficiently expresses a recombinant protein containing an immunological checkpoint molecular fragment, a helper T cell epitope fragment and an immunostimulatory molecule fragment in a recipient cell, and the recombinant protein can be significantly caused in a tumor patient.
  • the tumor-specific antigen immunoreaction which in turn causes specific killing of cytotoxic T lymphocytes (CTL) and specific antibodies against B lymphocyte secretion, achieves specific killing of tumor cells.
  • CTL cytotoxic T lymphocytes
  • the present invention also proposes a transgenic cell.
  • the transgenic cell carries the construct described above, and the transgenic cell proposed in the embodiment of the present invention can express the recombinant protein as described above to actively stimulate the anti-immunoassay in the patient body by active immunization.
  • Point such as antibodies to PD-L1 or PD-L2, mobilize spontaneously induced immune cell CTLs already present in the patient, and stimulate the production of anti-immunological checkpoints, such as PD-L1 or PD-L2 CTL, thereby specifically killing Tumor cells.
  • the transgenic cells are BL21, BL21 (DE3), BL21 (DE3) pLysS, DH10B, XL1-Blue, Pichia pastors, Kluyveromyces lactis, Sf9, Sf21, High-Five T, CHO cell line , HEK cell line, Hela cell line or COS cell line.
  • BL21, BL21 (DE3), BL21 (DE3) pLysS, DH10B and XL1-Blue are E. coli cells
  • Pichia pastors and Kluyveromyces lactis are yeast cells
  • Sf9, Sf21, and High-Five T are used for baculovirus.
  • CHO cell line, HEK cell line, Hela cell line or COS cell line is a mammalian cell line.
  • the transgenic cell described above can efficiently express the recombinant protein described above, and then the recombinant protein obtained by protein purification can be administered to a patient.
  • the patient actively stimulates the production of anti-PD-L1 or PD-L2 antibodies in the patient's body, mobilizes the spontaneously induced immune cell CTLs already present in the patient, and stimulates the production of anti-PD-L1 or PD-L2CTL. Specific killing of tumor cells.
  • the transgenic cell can be an antigen presenting cell and the transgenic cell is a DC cell.
  • the antigen presenting cell is derived from a patient, and the antigen presenting cell carrying the aforementioned construct can be further input into the patient, thereby realizing the continuous expression of the recombinant protein described above in the patient, and further Actively immunizing in the body to produce anti-PD-L1 or PD-L2 antibodies in vivo, mobilizing the spontaneously induced immune cell CTLs already present in the patient, and stimulating the production of anti-PD-L1 or PD-L2CTL, Specific killing of tumor cells.
  • the inventors have proposed the use of the aforementioned recombinant protein for the preparation of a medicament or a vaccine for preventing or treating a tumor.
  • the recombinant protein proposed by the embodiments of the present invention can cause a significant tumor-specific antigen immune response in a tumor patient, and effectively stimulates the production of an anti-immunological checkpoint, such as PD-L1 or PD-L2 antibody, to mobilize the spontaneous induction already existing in the patient.
  • the resulting immune cell CTL is stimulated to produce an anti-immunological checkpoint, such as PD-L1 or PD-L2CTL, which effectively kills the tumor cells specifically.
  • the recombinant protein proposed in the examples of the present invention has a use in the preparation of a medicament or vaccine effective for preventing or treating a tumor.
  • the present invention also proposes the use of the aforementioned recombinant protein for the preparation of a vaccine for the treatment of a viral infection.
  • the inventors have found that HBV, HCV, HIV, EBV virus-infected cells express PD-L1, and the vaccine prepared by the recombinant protein of the present invention can stimulate anti-PD-L1 in a patient.
  • the antibody mobilizes spontaneously induced immune cell CTLs already present in the patient and stimulates the production of anti-immunological checkpoints, such as PD-L1 CTL, to effectively kill cells infected with the above virus.
  • the invention provides a pharmaceutical composition.
  • the pharmaceutical composition comprises: the recombinant protein described above; and a pharmaceutically acceptable adjuvant.
  • the recombinant protein in the pharmaceutical composition proposed in the examples of the present invention can cause a significant specific antigen immune response, and the function of the adjuvant to enhance the immune response.
  • the pharmaceutical composition provided by the embodiment of the present invention effectively stimulates an anti-immunological checkpoint, such as a PD-L1 or PD-L2 antibody, in a tumor patient, and mobilizes the patient already.
  • viruses HBV, HCV, HIV, EBV
  • the invention provides a DC cell.
  • the DC cells are loaded with the recombinant protein described above.
  • the DC cells proposed in the embodiments of the present invention can treat tumor antigens in the recombinant protein (such as the immunological checkpoint molecular fragment described above), helper T cell epitope fragments, and immunospins.
  • the excimer fragments are presented to the cell surface, respectively, thereby effectively stimulating the production of anti-immunological checkpoints, such as PD-L1 or PD-L2 antibodies, mobilizing the spontaneously induced immune cell CTLs already present in the patient, and stimulating the production of anti-immune checkpoints, For example, PD-L1 or PD-L2CTL, thereby effectively killing tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV). .
  • viruses HBV, HCV, HIV, EBV
  • the invention provides a targeted immune cell population.
  • the targeted immune cell population is obtained by co-culture of DC cells with lymphocytes as described above.
  • the targeted immune cell population proposed in the embodiments of the present invention can specifically kill tumor cells, secrete antibodies that specifically bind tumor antigens, and achieve specific removal of tumor cells.
  • the invention provides a vaccine.
  • the vaccine comprises a recombinant protein as described above, a DC cell as described above or a targeted immune cell population as described above.
  • the recombinant protein, DC cell, and targeted immune cell population proposed in the examples of the present invention can cause a significant specific antigen immune response in a patient.
  • the vaccine according to the embodiment of the present invention can effectively stimulate the production of an anti-immunization checkpoint, such as a PD-L1 or PD-L2 antibody, mobilize the spontaneously induced immune cell CTL already existing in the patient, and stimulate An anti-immunization checkpoint, such as PD-L1 or PD-L2CTL, is generated to effectively kill tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
  • an anti-immunization checkpoint such as a PD-L1 or PD-L2 antibody
  • the invention provides an antibody.
  • the antibody specifically recognizes the recombinant protein described above, and the antibody proposed in the embodiment of the present invention specifically recognizes a tumor antigen.
  • the present invention finds that the antibody specifically recognizes an antigen, specifically binds to a tumor cell or a cell infected by a virus (HBV, HCV, HIV, EBV), thereby causing a tumor cell or a virus (HBV) Cells infected with HCV, HIV, EBV) are engulfed by phagocytic cells to achieve specific clearance of tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
  • a virus HCV, HCV, HIV, EBV
  • the present invention proposes a method of preparing an antibody.
  • the method comprises: immunizing an animal with the recombinant protein described above; collecting serum of the immunized animal; and purifying the antibody of interest from the serum.
  • the method for preparing an antibody proposed in the embodiments of the present invention is simple and convenient, and the antibody can specifically recognize the recombinant protein.
  • the therapeutic composition proposed by the present invention may comprise the recombinant protein described above, the nucleic acid described above, the aforementioned construct, the above-described transgenic cell, the aforementioned pharmaceutical composition
  • the therapeutic composition proposed by the embodiments of the present invention can directly or indirectly cause a specific antigen immune response, and achieve specificity to tumor cells or cells infected by viruses (HBV, HCV, HIV, EBV). Kill and clear.
  • the patient is administered a therapeutically effective amount of the recombinant protein described above, a pharmaceutical composition as described above, a DC cell as described above, a previously described targeted immune cell population, a vaccine as described above, or a front
  • the antibodies can be Effectively treat or prevent tumors that express PD-L1 or PD-L2.
  • administering refers to introducing a predetermined amount of a substance into a patient in some suitable manner.
  • the recombinant protein, pharmaceutical composition, DC cell, targeted immune cell population, vaccine or antibody in the embodiments of the present invention can be administered by any common route as long as it can reach the intended tissue.
  • Various modes of administration are contemplated, including peritoneal, venous, muscular, subcutaneous, cortical, oral, topical, nasal, pulmonary, and rectal, but the invention is not limited to these exemplary modes of administration.
  • the active ingredient of the orally administered composition should be coated or formulated to prevent its degradation in the stomach.
  • the compositions of the invention may be administered as an injectable preparation.
  • the pharmaceutical compositions of the invention may be administered using a particular device that delivers the active ingredient to the target cells.
  • the frequency and dose of administration of the recombinant protein, pharmaceutical composition, DC cell, targeted immune cell population, vaccine or antibody in the examples of the present invention can be determined by a plurality of related factors including the type of disease to be treated. , route of administration, patient age, sex, weight and severity of the disease, and the type of drug as the active ingredient.
  • the daily dose may be divided into 1 dose, 2 doses or multiple doses in a suitable form for administration once, twice or more times throughout the time period, as long as a therapeutically effective amount is achieved. .
  • terapéuticaally effective amount refers to an amount sufficient to significantly ameliorate certain symptoms associated with a disease or condition, that is, an amount that provides a therapeutic effect for a given condition and dosage regimen.
  • treatment is used to mean obtaining the desired pharmacological and/or physiological effect.
  • treatment encompasses administration of a recombinant protein, pharmaceutical composition, DC cell, targeted immune cell population, vaccine or antibody in an embodiment of the invention to a subject, including, but not limited to, administration comprising the agents described herein. The individual in need.
  • the recombinant protein and the use thereof, the pharmaceutical composition, the DC cell, the targeted immune cell population, the vaccine, the antibody, the method and system for treating and diagnosing cancer according to the embodiment of the present invention are the inventors of the present application. Hard creative labor and optimization work were discovered and completed.
  • the method of isolating DC cells from mouse bone marrow is as follows: bone marrow is punched out from the limbs of the mouse, and the bone marrow is passed through a nylon mesh, and red blood cells are removed with ammonium chloride. The cells were then thoroughly washed with RPMI-1640 medium, and then cultured in 2.5 ml of RPMI-1640 medium containing 10% FBS and 20 ng/ml recombinant mouse GM-CSF (rmGM-CSF). And 20 ng/ml recombinant mouse IL-4 (rmIL-4) (available from PeproTech, Inc., Rocky Hill, NJ).
  • the cell supernatant was removed and fresh medium was replaced with 20 ng/ml of rmGM-CSF and 20 ng/ml of rmIL-4.
  • the cells were cultured in an incubator at 37 ° C in a 5% CO 2 atmosphere. At 48 hours of the culture process, non-adherent granulocytes were removed and fresh medium was replaced. After 7 days of cell culture, about 80% or more of the cells expressed DC cell-specific markers by FACS analysis.
  • Recombinant protein was added to bone marrow-derived DC cells (obtained after 5-7 days of bone marrow cell culture) to activate DC cells, and after 8 hours, the cells were washed with PBS three times, and after further culture for 136 hours, DC cells were used as Immunization model.
  • antigen-activated DC cells were stimulated with 100 ng/ml LPS (Sigma, St. Louis, MO) for 24 hours, and the cells were washed with PBS and injected into mice via the soles of mice (C57BL/6, Jackson). Laboratory) In vivo.
  • rodent lung cancer cells CMT167 (C57BL) (purchased from the European Collection of Authenticated Cell Cultures (ECAC)) were introduced into the right abdominal cavity of syngeneic C57BL/6 mice by subcutaneous injection. After tumor inoculation, mice were randomized and injected into antigen-activated DC cells or PBS in different groups on different days. Tumor volume was measured 2 or 3 times a week using a caliper.
  • the CD8+ CTL response was assessed by standard chromium release assays.
  • Standard chromium release assessment experiments were performed by measuring the ability of spleen cells to lyse target cells in vitro. Splenocytes from immunized mice were restimulated in vitro with RPMI containing the polypeptide for 4 to 6 days. Target cells and control cells were labeled with 51Cr sodium chromate solution for 90 min. Different numbers of effector cells were co-cultured with a certain number (1 ⁇ 104/well) of target cells for 3 hours at 37° C. in a 96-well plate v-bottom plate (200 microliters of medium per well). 100 microliters of supernatant was collected from every 3 wells.
  • the dissolution rate is calculated by the following formula: (experimental chromium release amount - spontaneous chromium release amount) / (maximum chromium release amount - spontaneous chromium release amount) X 100.
  • the amount of chromium released was achieved by co-cultivation, placing the wells on a centrifuge and centrifuging, and calculating the radiation activity in the supernatant by a gamma counter (purchased from Beckman Coulter, Inc., Fullerton, CA) ( Chromium release).
  • Synthesis of fusion gene 1 contains part of human PD-L1 sequence or PD-L2 sequence (Accession number GenBank: AF177937.1), intact PADRE helper T cell epitope sequence and complete GM-CSF, IL-12 or RANTES sequence (Accession number GenBank: M11734.1) and flanking cloning site sequences (fusion gene-structure shown in Figure 1) (synthesized by GENEWIZ, South Plainfield, NJ, USA).
  • Synthetic Fusion Gene 2 Contains a partial human PD-L1 sequence or a PD-L2 sequence (GenBank: AF177937.1) and an intact helper T cell PADRE epitope sequence.
  • the target recombinant plasmid was electroporated into Escherichia coli BL21(DE3) (Novagen) competent cells, and then Escherichia coli BL21 (DE3) was seeded on LB agar plates (containing 50 ⁇ g/ml of ampicillin). Amplification culture is carried out.
  • the method of recombinant protein expression described below is one of a series of experiments under different experimental conditions.
  • the frozen cell pellet was resuspended in lysate (50 mM Tris, pH 8.0, 1 mM EDTA and 1 mM PMSF) with a mass to volume ratio of cell pellet to lysate of 1:10.
  • the inclusion bodies containing the recombinant protein were restored to activity under the conditions of French Pressure (Constant Systems LTD) of 137.9 MPa.
  • French Pressure Constant Systems LTD
  • an equal volume of lysate is added to dilute to reduce viscosity, which is more advantageous for obtaining inclusion bodies.
  • the lysed solution was centrifuged at 48,000 x g for 30 min to cause inclusion bodies to precipitate.
  • the supernatant was discarded and the pellet was washed three times to remove endotoxin, protein and DNA from the host cells.
  • the solution used for the first pass of cleaning contained 50 mM Tris, pH 8.0, 5 mM EDTA and 2% Triton x-100.
  • the solution used for the second pass of cleaning contained 50 mM Tris, pH 8.0, 5 mM EDTA, 1% sodium deoxycholate.
  • the solution used for the third cleaning consisted of 50 mM Tris, pH 8.0, 5 mM EDTA, and 1 M NaCl. After washing, the pellet was resuspended at room temperature with a special lysate (mass to volume ratio of 1:40), stirred for 30 min and centrifuged.
  • the solubilized protein was further purified by a Ni-NTA Fast Start Kit (Qiagen).
  • the eluted proteins were analyzed by 12% SDS-PAGE gel electrophoresis, and the protein concentration was determined by Bradford et al. (Bio-Rad Laboratories). Recombinant proteins with a purity greater than 90% were stored at -20 °C for subsequent studies.
  • Example 4 DC cells loaded with a fusion protein comprising human PD-L1 were effective in inducing anti-PD-L1 antibody production and CTL responses in mice
  • DC cells loaded with the PD-L1 fusion protein were able to induce anti-PD-L1 antibody production and CTL responses in mice.
  • DC cells loaded with PD-L1 fusion protein in mice The ability of the body to elicit a PD-L1-specific response was verified by immunizing mice with DC cells.
  • PD-L1 ⁇ -PADRE Th-GM-CSF recombinant protein
  • PD-L1 ⁇ protein
  • immunostimulatory factor recombinant GM-CSF, Genzyme, Tarzana, CA
  • the levels of PD-L1-specific IgG in the serum of each group of rats were determined by ELISA, and the recombinant PD-L1 protein (Abeam, Cambridge, MA, USA) was plated every 3 wells of the ELISA plate, and the ELISA value was passed through serum (1). : 100 times dilution) The mean value of OD450nm values ⁇ SD was obtained.
  • Figure 2 shows that iPD-L1-Vax DC cells can induce significant anti-PD-L1 antibody responses, whereas PD-L1 ⁇ protein-loaded DC cells can only induce weak anti-PD- L1 antibody reaction.
  • spleen cells were isolated from tumor cell suspensions vaccinated with immunized mice.
  • the isolated T cells were re-stimulated by PD-L1 recombinant protein-activated DC cells (10 ⁇ g/ml), and then the in vitro 51Cr release test was performed, and the 51Cr release test was performed according to the specified T/E (target cell: effector cell) ratio.
  • the target cell was the PD-L1+ murine lung cancer cell line CMT167 (C57BL) (available from the European Collection of Authenticated Cell Cultures (ECACC)).
  • Figure 3 shows that iPD-L1-Vax DC cells were able to induce significant anti-PD-L1 CTL responses, whereas DC cells loaded with PD-L1 ⁇ protein induced only weak anti-PD-L1 CTLs. reaction.
  • DC cells DC cells were loaded with recombinant protein (PD-L1 ⁇ -PADRE Th-GM-CSF) (iPD-L1-Vax), protein PD-L1 ⁇ , immunostimulatory factor (GMCSF), or PBS, and DC cells were pre-treated Maturation was stimulated twice in vitro using LPS in vitro. Tumor growth was measured every 3 to 4 days after immunization.
  • Figure 4 shows that the immunization of mice with iPD-L1-Vax DC can significantly inhibit the growth of PD-L1+ lung cancer, but with DC immunization with protein PD-L1 ⁇ or PBS. Mice did not inhibit the growth of PD-L1+ lung cancer.
  • the inventors examined the loading of recombinant protein (PD-L1 ⁇ -PADRE Th-IL-12 or PD-L1 ⁇ -PADRE Th-RANTES or PD-L2 ⁇ -PADRE Th-GM-CSF or PD-L2 ⁇ - PADRE Th-IL-12 or DC cells of PD-L1 ⁇ -PADRE Th-RANTES or PD-L1/L2 ⁇ -PADRE Th-GM-CSF or PD-L1/L2 ⁇ -PADRE Th-IL-12 or PD-L1/L2 ⁇ -PADRE Th-RANTES)
  • the condition of inducing anti-PD-L1 or anti-PD-L2 antibody production and CTL reaction in mice and the case of vaccination controlling the growth of PD-L1+ or PD-L2+ lung cancer, the experimental methods are as described in Example 4 and Example 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une protéine recombinante et ses utilisations. La protéine recombinante comprend un segment de molécule de point de contrôle immunitaire, un segment d'épitope de lymphocyte T auxiliaire et un segment de molécule immunostimulante.
PCT/CN2017/080144 2016-04-11 2017-04-11 Protéines recombinantes pd-l1 et pd-l2 et leurs utilisations WO2017177908A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610222458.0A CN107286245B (zh) 2016-04-11 2016-04-11 Pd-l1和pd-l2重组蛋白及其用途
CN201610222458.0 2016-04-11

Publications (1)

Publication Number Publication Date
WO2017177908A1 true WO2017177908A1 (fr) 2017-10-19

Family

ID=60041421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/080144 WO2017177908A1 (fr) 2016-04-11 2017-04-11 Protéines recombinantes pd-l1 et pd-l2 et leurs utilisations

Country Status (2)

Country Link
CN (1) CN107286245B (fr)
WO (1) WO2017177908A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230167164A1 (en) * 2020-12-23 2023-06-01 Immunowake Inc. Immunocytokines and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116375881A (zh) * 2021-12-31 2023-07-04 广州国家实验室 融合蛋白疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101002937A (zh) * 2006-08-23 2007-07-25 中国人民解放军第四军医大学 重组人His－TT－B7－H1IgV肿瘤疫苗及其制备方法
CN103965363A (zh) * 2013-02-06 2014-08-06 上海白泽生物科技有限公司 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1318105A (zh) * 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
CN103768604B (zh) * 2012-10-24 2016-03-30 北京圣沃德生物科技有限公司 治疗性肿瘤疫苗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101002937A (zh) * 2006-08-23 2007-07-25 中国人民解放军第四军医大学 重组人His－TT－B7－H1IgV肿瘤疫苗及其制备方法
CN103965363A (zh) * 2013-02-06 2014-08-06 上海白泽生物科技有限公司 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CONG, HUA ET AL.: "Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome et al.", IMMUNOME RESEARCH, vol. 6, no. 12, 31 December 2010 (2010-12-31), pages 1 - 15, XP055429034 *
PENG, XIAOMOU ET AL.: "Effect of exogenous epitopes of helper T lymphocyte on humoral immunity of HBV S gene DNA immunity", NATIONAL MEDICAL JOURNAL OF CHINA, vol. 83, no. 3, 10 February 2003 (2003-02-10) *
ZHENG, XIUHUI ET AL.: "The Application of Molecular Adjuvant in DNA Vaccine", JOURNAL OF INTERNATIONAL REPRODUCTIVE HEALTH/FAMILY PLANNING, vol. 28, no. 3, 31 May 2009 (2009-05-31), pages 205 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230167164A1 (en) * 2020-12-23 2023-06-01 Immunowake Inc. Immunocytokines and uses thereof

Also Published As

Publication number Publication date
CN107286245A (zh) 2017-10-24
CN107286245B (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
Porgador et al. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Lin et al. A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells
JP6134763B2 (ja) ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
Wells et al. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity
JP5087925B2 (ja) 新規癌抗原ペプチド及びその用途
JP2016516723A (ja) ガンワクチン及びそれを用いた治療方法
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2017177907A1 (fr) Vaccins contre les tumeurs pd-l1 et pd-l2 de point de contrôle immunitaire
CN106632694B (zh) 一种重组蛋白及药物组合物与应用
CN107488235B (zh) 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用
Mohit et al. The contribution of NT‐gp96 as an adjuvant for increasing HPV16 E7‐specific immunity in C57BL/6 mouse model
WO2018094569A1 (fr) Polypeptide et son application
TW201938793A (zh) 一種新型疫苗佐劑
Mikysková et al. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF
Moeini et al. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine
WO2018090257A1 (fr) Polypeptide et son application
WO2017177908A1 (fr) Protéines recombinantes pd-l1 et pd-l2 et leurs utilisations
Kollessery et al. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model
EP1829893B1 (fr) Formulations inmunotherapeutiques a capacite de neutralisation de l'interleukine-2
Kim et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination
Indrová et al. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I− tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines
RU2283129C1 (ru) Белковопептидный противоопухолевый композит, клеточный препарат, активированный этим композитом, и способ профилактики или лечения опухолей
WO2018094570A1 (fr) Polypeptide et son application
WO2018098636A1 (fr) Polypeptide et son application
CN102838679A (zh) Her2-neu抗原阳性肿瘤治疗性疫苗的制备及应用

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17781884

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17781884

Country of ref document: EP

Kind code of ref document: A1